Endometrial thickness of postmenopausal breast cancer patients treated with tamoxifen

Gynecological Endocrinology

Volumn 21, Issue 6, 2005, Pages 312-316

  Salazar, Edith L ^a,c   Paredes, Adrián ^a   Calzada, Leobardo ^b  

^a INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^b Health Center (T III) Dr Manuel Escondria   (Mexico)

^c Sanitary Jurisdiction Alvaro Obregon of the Public Health Service of Distrito Federal ^*  (Mexico)

Author keywords

Breast cancer; Endometrium; Tamoxifen

Indexed keywords

FOLLITROPIN; LUTEINIZING HORMONE; TAMOXIFEN;

ADULT; AGED; ARTICLE; BODY MASS; BREAST CANCER; CONTROLLED STUDY; DRUG EFFECT; ENDOMETRIUM; FEMALE; FOLLITROPIN BLOOD LEVEL; HISTOPATHOLOGY; HUMAN; LUTEINIZING HORMONE BLOOD LEVEL; MAJOR CLINICAL STUDY; MENARCHE; MENOPAUSE; POSTMENOPAUSE; PRIORITY JOURNAL; SMOKING;

AGED; ANTINEOPLASTIC AGENTS, HORMONAL; BODY WEIGHTS AND MEASURES; BREAST NEOPLASMS; ENDOMETRIUM; ESTRADIOL; FEMALE; FOLLICLE STIMULATING HORMONE; HUMANS; LUTEINIZING HORMONE; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN; TIME FACTORS; ULTRASONOGRAPHY, DOPPLER, COLOR; UTERINE DISEASES;

EID: 30344433252     PISSN: 09513590     EISSN: 14730766     Source Type: Journal    
DOI: 10.1080/09513590500430450     Document Type: Article

References (23)

1. Clarke R, Leonessa F, Welch JN, Skaar TC. Cellular and molecular pharmacology of antiestrogen action and resistance. Pharmacol Rev 2001;53:25-71.
2. Hutcheson IR, Knowlden JM, Madden TA, Barrow D, Gee JM, Wakeling AE, Nicholson RI. Oestrogen receptor-mediated modulation of the EGFR/MAPK pathway in tamoxifen-resistant MCF-7 cells. Breast Cancer Res Treat 2003;81:81-93.
3. Osborne CK, Elledge RM, Fuqua SAW. Estrogen receptors in breast cancer therapy. Sci Med 1996;3:32-41.
4. Calzada SL, Salazar EL, Pedron N. Relationship between the outcome of tamoxifen therapy in ductal and lobular infiltration breast cancer and estradiol and progesterone receptor values. Med Sci Res 1995;23:771-772.
5. Early Breast Cancer Trialists' Collaborative Group. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 1998;351:1451-1467.
6. Rutqvist LE, Cedermark B, Glas U, Mattsson A, Skoog L, Somell A, Theve T, Wilking N, Askergren J, Hjalmar ML, et al. Contralateral primary tumors in breast cancer patients in randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 1991;83:1299-1306.
7. Fisher B, Constantino JP, Wickerham DI. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst 1998;90:1371-1388.
8. Malfetano JH. Tamoxifen: associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 1990;39:82-84.
9. Fujimoto J, Hori M, Ichigo S, Morishita S, Tamaya T. Estrogen activates invasiveness of endometrial cancer cells to the interstitium. Invasion Metastasis 1995; 15:135-143.
10. Liu M-M, Albanese C, Anderson C, Hilty K, Webb P, Uht RM, Price RH Jr, Pestell RG, Kushner PJ. Opposing action of estrogen receptors α and β on cyclin D1 gene expression. J Biol Chem 2002;277:24353-24360.
11. Fujimoto J, Hori M, Ichigo S, Morishita S, Tamaya T. Estrogen activates migration potential of endometrial cancer cells through basement membrane. Tumor Biol 1996;17:48-57.
12. Hayashi SI, Eguchi H, Tanimoto K. The expression and function of estrogen receptor α and β in human breast cancer and its clinical application. Endocr Relat Cancer 2003;10:193-202.
13. Morán C, Calzada L, Salazar EL, Bermúdez JA. Estradiol and progesterone endometrial receptors and body fat distribution in obese women. Gynecol Obstet Invest 1996;42:117-119.
14. Calzada L, Martinez JM, Pedrón N. Obesity, estradiol and progesterone receptors and their relation to menstrual status in breast cancer. Med Sci Res 1999;27:401-402.
15. Lahti E, Blanco G, Kauppila A, Apaja-Sarkkinen M, Taskinen PJ, Laatikainen T. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660-664.
16. Salazar EL, Paredes A, Moreno E, Calzada SL. Hormone receptors and cellular differentiation: relationship/expression in breast carcinoma. Adv Reprod 1998;2:71-77.
17. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic or immune therapy: 133 randomized trials involving 31,000 recurrent and 24,000 deaths in 75,000 women. Lancet 1992;339:1-85.
18. Cohen I, Beyth Y, Tepper R, Fiber A, Shapira J, Cordoba M. Adenomyosis in postmenopausal breast cancer patients treated with tamoxifen: a new entity? Gynecol Oncol 1995;56:86-91.
19. Chang CK, Chen P, Leu FJ, Lou M. Florid polypoid endometriosis exacerbated by tamoxifen therapy in breast cancer. Obstet Gynecol 2003;102:1127-1130.
20. Bese T, Simsek Y, Bese N, Ilvan S, Arvas M. Extensive pelvic endometriosis with malignant change in tamoxifen-treated postmenopausal women. Int J Gynecol Cancer 2003;13:376-380.
21. Rose PG, Alvarez BM, MacLennan GT. Exacerbation of endometriosis as a result of premenopausal tamoxifen exposure. Am J Obstet Gynecol 2000;183:507-508.
22. Hulka BS. Protection against endometrial carcinoma by combination-product oral contraceptives. J Am Med Assoc 1982;247:475-477.
23. Sah E, Sato K. Clinical effects of danazol on endometrial hyperplasia in menopausal and postmenopausal women. Cancer 1990;66:983-988.